https://www.selleckchem.com/products/ly333531.html
that complex IV was selective against cancer cells. The viability assays revealed that complex IV, bearing a NO group and a modified lysine residue, was able to release NO and croses tumor cell membranes. In this work, the Complex IV was the most active ruthenium bipyridine complex against the mammalian breast cancer cells MCF-7 and MDA-MB231 it was approximately twice as active as cisplatin, whilst complexes I-III proved to be less cytotoxic than complex IV. Additional tests using healthy MCF 10A cells showed that complexes II-IV were
Like
Comment
Share
